Tags

Type your tag names separated by a space and hit enter

Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Dement Geriatr Cogn Disord 2008; 26(6):522-7DG

Abstract

BACKGROUND

Serum amyloid P component (SAP), present in amyloid-beta (Abeta) plaques in Alzheimer's disease (AD), may protect Abeta deposits against proteolysis, thereby promoting plaque formation. The aim was to investigate if SAP levels in cerebrospinal fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive impairment (MCI) patients, and to identify incipient AD among MCI patients.

METHODS

SAP levels in CSF and serum were determined in 30 controls, 67 MCI and 144 AD patients. At follow-up, 39 MCI patients had progressed to dementia, while 25 had remained stable (mean follow-up time: 2.6 +/- 1.0 and 2.1 +/- 0.8 years).

RESULTS

Cross-sectionally no differences were found in SAP levels in CSF and serum between the groups. MCI patients that had progressed to dementia at follow-up had lower CSF SAP levels (13 microgram/l, range 3.3-199.3 microgram/l) than MCI nonprogressors (20.2 microgram/l, range 7.0-127.7 microgram/l; p < 0.05) [corrected]. A low CSF SAP level was associated with a 2-fold increased risk of progression to AD (hazard ratio = 2.2; 95% confidence interval = 0.9-5.4).

CONCLUSION

Our data suggest that measurement of CSF SAP levels can aid in the identification of incipient AD among MCI patients.

Authors+Show Affiliations

Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. n.verwey@vumc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19052452

Citation

Verwey, Nicolaas A., et al. "Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease." Dementia and Geriatric Cognitive Disorders, vol. 26, no. 6, 2008, pp. 522-7.
Verwey NA, Schuitemaker A, van der Flier WM, et al. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;26(6):522-7.
Verwey, N. A., Schuitemaker, A., van der Flier, W. M., Mulder, S. D., Mulder, C., Hack, C. E., ... Veerhuis, R. (2008). Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 26(6), pp. 522-7. doi:10.1159/000178756.
Verwey NA, et al. Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. Dement Geriatr Cogn Disord. 2008;26(6):522-7. PubMed PMID: 19052452.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. AU - Verwey,Nicolaas A, AU - Schuitemaker,Alie, AU - van der Flier,Wiesje M, AU - Mulder,Sandra D, AU - Mulder,Cees, AU - Hack,C Erik, AU - Scheltens,Philip, AU - Blankenstein,Marinus A, AU - Veerhuis,Robert, Y1 - 2008/12/02/ PY - 2008/10/01/accepted PY - 2008/12/5/pubmed PY - 2009/4/11/medline PY - 2008/12/5/entrez SP - 522 EP - 7 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 26 IS - 6 N2 - BACKGROUND: Serum amyloid P component (SAP), present in amyloid-beta (Abeta) plaques in Alzheimer's disease (AD), may protect Abeta deposits against proteolysis, thereby promoting plaque formation. The aim was to investigate if SAP levels in cerebrospinal fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive impairment (MCI) patients, and to identify incipient AD among MCI patients. METHODS: SAP levels in CSF and serum were determined in 30 controls, 67 MCI and 144 AD patients. At follow-up, 39 MCI patients had progressed to dementia, while 25 had remained stable (mean follow-up time: 2.6 +/- 1.0 and 2.1 +/- 0.8 years). RESULTS: Cross-sectionally no differences were found in SAP levels in CSF and serum between the groups. MCI patients that had progressed to dementia at follow-up had lower CSF SAP levels (13 microgram/l, range 3.3-199.3 microgram/l) than MCI nonprogressors (20.2 microgram/l, range 7.0-127.7 microgram/l; p < 0.05) [corrected]. A low CSF SAP level was associated with a 2-fold increased risk of progression to AD (hazard ratio = 2.2; 95% confidence interval = 0.9-5.4). CONCLUSION: Our data suggest that measurement of CSF SAP levels can aid in the identification of incipient AD among MCI patients. SN - 1421-9824 UR - https://www.unboundmedicine.com/medline/citation/19052452/Serum_amyloid_p_component_as_a_biomarker_in_mild_cognitive_impairment_and_Alzheimer's_disease_ L2 - https://www.karger.com?DOI=10.1159/000178756 DB - PRIME DP - Unbound Medicine ER -